Supplementary Table 4. Sensitivity analysis on the effect modification by TBIL in participants with normal TBIL values

Outcome	Group	N	n (%)	Adj. OR/cOR (95% CI)*	*P*	*P* for interaction
Presence of CSVD (Wardlaw)†	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276	258 (20.2)	Ref.		0.047
	Hypertension	943	389 (41.3)	1.86 (1.41–2.44)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	460	125 (27.2)	Ref.		
	Hypertension	370	157 (42.4)	1.08 (0.69–1.67)	0.747	
Presence of CSVD (Rothwell)†	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276	391 (30.6)	Ref.		0.043
	Hypertension	943	514 (54.5)	1.84 (1.43–2.38)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	460	165 (35.9)	Ref.		
	Hypertension	370	193 (52.2)	1.11 (0.73–1.68)	0.617	
Total CSVD burden (Wardlaw)‡	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276		Ref.		0.106
	Hypertension	943		1.88 (1.44–2.46)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	460		Ref.		
	Hypertension	370		1.21 (0.80–1.85)	0.369	
Modified total CSVD burden (Rothwell)‡	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276		Ref.		0.057
	Hypertension	943		1.85 (1.45–2.36)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	460		Ref.		
	Hypertension	370		1.19 (0.80–1.76)	0.393	

Participants with abnormal elevated TBIL were excluded. Abnormal elevated TBIL was defined as the TBIL concentrations of more than 2 times the upper limit of the normal range (41 μmol/L). All models were adjusted for age, sex, body mass index, current smoking, current drinking, diabetes, dyslipidemia, antihypertensive medication, antiplatelet medication, anticoagulant medication, and alanine aminotransferase and aspartate aminotransferase levels.
TBIL, total bilirubin; Adj., adjust; OR, odds ratio; cOR, common odds ratio; CI, confidence interval; CSVD, cerebral small vessel disease; Ref., reference.
*The association of hypertension with the presence of CSVD was evaluated using OR, while with CSVD burden was evaluated using cOR. The product term of the hypertension state and TBIL group was included in the model to assess the effect modification by TBIL; †Presence of CSVD was defined as total CSVD or modified total CSVD burden scores ≥1; ‡Total and modified total CSVD burdens were classified as grade 0 (total or modified total CSVD burden score 0), grade 1 (total or modified total CSVD burden score 1), grade 2 (total or modified total CSVD burden score 2–3), or grade 3 (total or modified total CSVD burden score ≥4).

https://doi.org/10.5853/jos.2025.01935